Skip to main content
Top
Published in: Acta Diabetologica 6/2014

01-12-2014 | Original Article

Coronary artery disease as an independent predictor of survival in patients with type 2 diabetes and Charcot neuro-osteoarthropathy

Authors: Dominik Bergis, Pia Maria Bergis, Norbert Hermanns, Karl Zink, Thomas Haak

Published in: Acta Diabetologica | Issue 6/2014

Login to get access

Abstract

Aims

Charcot neuro-osteoarthropathy (CN) is a rare complication of diabetic foot syndrome associated with chronic inflammation of the foot and severe, limb-threatening musculoskeletal deformities. Aim of this study was to investigate patients with CN for comorbidities, amputations, ulcers, secondary diseases and mortality.

Methods

The study was conducted at a specialized German hospital for patients with diabetes. One-hundred and eleven patients were enrolled, and their course was followed over a period of 15 years. Association of CN with comorbidity, foot ulcers, amputations and mortality was assessed. Clinical course of patients was followed using two standardized questionnaires.

Results

Presence of CN was significantly associated with diabetic retinopathy (p = 0.047), plantar (p < 0.001), tarsal (p = 0.032) and middle-foot ulcers (p = 0.01). A significant correlation between the presence of CN and a history of amputations was seen (p = 0.022). Patients were at increased risk to suffer from subsequent amputations during follow-up when micro- and macrovascular comorbidities such as retinopathy (p = 0.01) and peripheral artery disease (p < 0.001) were present. Additionally, coronary artery disease (CHD) was identified as an independent predictor of mortality in the cohort of this study (OR 6.192, 95 % CI 1.155–33.208, p = 0.033). Median overall survival of patients with CN and CHD was significantly shorter than OS of patients without CHD (7.8 vs. 13.1 years, p = 0.0045, HR 2.8437, 95 % CI 0.9818–8.2364).

Conclusions

In our study, CHD was the most important factor of survival in CN patients. For optimal management of CN, adequate diagnostics and treatment of CHD according to current guidelines should be considered.
Appendix
Available only for authorised users
Literature
2.
go back to reference Hochlenert D, Engels G (2007) Integrated management in patients with diabetic foot syndrome. MMW Fortschr Med 149(17):41–43PubMed Hochlenert D, Engels G (2007) Integrated management in patients with diabetic foot syndrome. MMW Fortschr Med 149(17):41–43PubMed
4.
go back to reference Morbach S, Muller E, Reike H, Risse A, Rümenapf G, Spraul M (2009) Diagnosis, treatment, follow up and prevention of the diabetic foot. Diabetol Stoffwechs 4(5):301–325CrossRef Morbach S, Muller E, Reike H, Risse A, Rümenapf G, Spraul M (2009) Diagnosis, treatment, follow up and prevention of the diabetic foot. Diabetol Stoffwechs 4(5):301–325CrossRef
5.
go back to reference Kazuga M (2004) Etiology of and therapy for type-2 diabetes mellitus. Nihon Naika Gakkai zasshi J Jpn Soc Intern Med 93(3):527–531CrossRef Kazuga M (2004) Etiology of and therapy for type-2 diabetes mellitus. Nihon Naika Gakkai zasshi J Jpn Soc Intern Med 93(3):527–531CrossRef
6.
go back to reference Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH, Hartemann A, Game F, Jeffcoate W, Jirkovska A, Jude E, Morbach S, Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L (2011) The Charcot foot in diabetes. J Am Podiatr Med Assoc 101(5):437–446PubMedCrossRef Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH, Hartemann A, Game F, Jeffcoate W, Jirkovska A, Jude E, Morbach S, Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L (2011) The Charcot foot in diabetes. J Am Podiatr Med Assoc 101(5):437–446PubMedCrossRef
7.
go back to reference Schon LC, Easley ME, Weinfeld SB (1998) Charcot neuroarthropathy of the foot and ankle. Clin Orthop Relat Res 349:116–131PubMedCrossRef Schon LC, Easley ME, Weinfeld SB (1998) Charcot neuroarthropathy of the foot and ankle. Clin Orthop Relat Res 349:116–131PubMedCrossRef
9.
go back to reference Pinzur MS, Shields N, Trepman E, Dawson P, Evans A (2000) Current practice patterns in the treatment of Charcot foot. Foot Ankle Int 21(11):916–920PubMed Pinzur MS, Shields N, Trepman E, Dawson P, Evans A (2000) Current practice patterns in the treatment of Charcot foot. Foot Ankle Int 21(11):916–920PubMed
10.
go back to reference Slater RA, Ramot Y, Buchs A, Rapoport MJ (2004) The diabetic Charcot foot. Isr Med Assoc J 6(5):280–283PubMed Slater RA, Ramot Y, Buchs A, Rapoport MJ (2004) The diabetic Charcot foot. Isr Med Assoc J 6(5):280–283PubMed
12.
go back to reference Menghini R, Uccioli L, Vainieri E, Pecchioli C, Casagrande V, Stoehr R, Cardellini M, Porzio O, Rizza S, Federici M (2013) Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but not neuropathic ulcers from patients with type 2 diabetes mellitus. Acta Diabetol 50(6):907–910. doi:10.1007/s00592-013-0478-6 PubMedCrossRef Menghini R, Uccioli L, Vainieri E, Pecchioli C, Casagrande V, Stoehr R, Cardellini M, Porzio O, Rizza S, Federici M (2013) Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but not neuropathic ulcers from patients with type 2 diabetes mellitus. Acta Diabetol 50(6):907–910. doi:10.​1007/​s00592-013-0478-6 PubMedCrossRef
14.
go back to reference Frykberg RG, Mendeszoon E (2000) Management of the diabetic Charcot foot. Diabetes Metab Res Rev 16(Suppl 1):S59–S65. doi:10.1002/1520-7560(200009/10)16:1+<::AID-DMRR134>3.0.CO;2-N Frykberg RG, Mendeszoon E (2000) Management of the diabetic Charcot foot. Diabetes Metab Res Rev 16(Suppl 1):S59–S65. doi:10.1002/1520-7560(200009/10)16:1+<::AID-DMRR134>3.0.CO;2-N
16.
go back to reference Levin ME (1995) Preventing amputation in the patient with diabetes. Diabetes Care 18(10):1383–1394PubMed Levin ME (1995) Preventing amputation in the patient with diabetes. Diabetes Care 18(10):1383–1394PubMed
17.
go back to reference Dissanayake SU, Bowling FL, Jude EB (2012) The diabetic Charcot foot. Curr Diabetes Rev 8(3):191–194PubMedCrossRef Dissanayake SU, Bowling FL, Jude EB (2012) The diabetic Charcot foot. Curr Diabetes Rev 8(3):191–194PubMedCrossRef
18.
go back to reference Mannucci E, Genovese S, Monami M, Navalesi G, Dotta F, Anichini R, Romagnoli F, Gensini G (2014) Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study—the DANTE (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study. Acta Diabetol 51(3):435–440. doi:10.1007/s00592-013-0533-3 PubMedCrossRef Mannucci E, Genovese S, Monami M, Navalesi G, Dotta F, Anichini R, Romagnoli F, Gensini G (2014) Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study—the DANTE (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study. Acta Diabetol 51(3):435–440. doi:10.​1007/​s00592-013-0533-3 PubMedCrossRef
20.
go back to reference Pitocco D, Marano R, Di Stasio E, Scavone G, Savino G, Zaccardi F, Rizzi A, Martini F, Musella T, Silvestri V, Costantini F, Galli M, Caputo S, Bonomo L, Ghirlanda G (2014) Atherosclerotic coronary plaque in subjects with diabetic neuropathy: the prognostic cardiovascular role of Charcot neuroarthropathy: a case-control study. Acta Diabetol 51(4):587–593. doi:10.1007/s00592-014-0559-1 PubMed Pitocco D, Marano R, Di Stasio E, Scavone G, Savino G, Zaccardi F, Rizzi A, Martini F, Musella T, Silvestri V, Costantini F, Galli M, Caputo S, Bonomo L, Ghirlanda G (2014) Atherosclerotic coronary plaque in subjects with diabetic neuropathy: the prognostic cardiovascular role of Charcot neuroarthropathy: a case-control study. Acta Diabetol 51(4):587–593. doi:10.​1007/​s00592-014-0559-1 PubMed
26.
go back to reference Samann A, Pofahl S, Lehmann T, Voigt B, Victor S, Moller F, Muller UA, Wolf G (2012) Diabetic nephropathy but not HbA1c is predictive for frequent complications of Charcot feet—long-term follow-up of 164 consecutive patients with 195 acute Charcot feet. Exp Clin Endocrinol Diabetes 120(6):335–339. doi:10.1055/s-0031-1299705 PubMedCrossRef Samann A, Pofahl S, Lehmann T, Voigt B, Victor S, Moller F, Muller UA, Wolf G (2012) Diabetic nephropathy but not HbA1c is predictive for frequent complications of Charcot feet—long-term follow-up of 164 consecutive patients with 195 acute Charcot feet. Exp Clin Endocrinol Diabetes 120(6):335–339. doi:10.​1055/​s-0031-1299705 PubMedCrossRef
Metadata
Title
Coronary artery disease as an independent predictor of survival in patients with type 2 diabetes and Charcot neuro-osteoarthropathy
Authors
Dominik Bergis
Pia Maria Bergis
Norbert Hermanns
Karl Zink
Thomas Haak
Publication date
01-12-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 6/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0669-9

Other articles of this Issue 6/2014

Acta Diabetologica 6/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.